Triple
T33388652
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Teprotumumab |
E854987
|
entity |
| Predicate | instanceOf |
P0
|
FINISHED |
| Object | IGF-1R inhibitor |
C58256
|
CONCEPT FINISHED |
How this triple was built (1 step)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
CD
Concept disambiguation
gpt-5-mini-2025-08-07
Target class: IGF-1R inhibitor Context triple: [Teprotumumab, instanceOf, IGF-1R inhibitor]
-
A.
angiopoietin-2 inhibitor
An angiopoietin-2 inhibitor is a therapeutic agent that selectively blocks the activity of angiopoietin-2 to stabilize blood vessels, reduce pathological angiogenesis, and modulate vascular inflammation in diseases such as cancer and ocular disorders.
-
B.
tyrosine kinase inhibitor
A tyrosine kinase inhibitor is a drug that blocks the activity of tyrosine kinases—enzymes involved in cell signaling pathways—to prevent uncontrolled cell growth and proliferation, commonly used in cancer therapy.
-
C.
GIP receptor agonist
A GIP receptor agonist is a compound that binds to and activates the glucose-dependent insulinotropic polypeptide (GIP) receptor, enhancing insulin secretion and improving glucose regulation.
-
D.
CDK4/6 inhibitor
A CDK4/6 inhibitor is a targeted anticancer drug that blocks cyclin-dependent kinases 4 and 6 to halt cell cycle progression from G1 to S phase, thereby inhibiting tumor cell proliferation.
-
E.
Janus kinase inhibitor
A Janus kinase inhibitor is a drug that selectively blocks Janus kinase (JAK) enzymes to modulate cytokine signaling and reduce inflammation or abnormal immune activity in various diseases.
- F. None of above. chosen
Provenance (1 batch)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3496d54048190a1cb91fdd7caa6ea |
completed | April 30, 2026, 12:22 p.m. |
Created at: May 1, 2026, 1:35 a.m.